Updates
Important Updates

- All J & J COVID-19 vaccine has expired as of 5/6/2023

- As of 5/11/2023 CDC Vaccine Finder reporting has changed from weekly reporting on Fridays to monthly reporting by 4 a.m. ET on the second Wednesday of the month.
COVID-19 Vaccine Presentations Available to Order in ASIIS Job Aid

*NEW* The monovalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States.

These are the monovalent products no longer available to order in ASIIS:

- Comirnaty (NDC 00069-2025-10)
- Pediatric Pfizer Orange Cap (NDC 59267-1055-04)
- Pediatric Pfizer Maroon Cap (NDC 59267-0078-04)
- Pediatric Moderna Blue Cap with Magenta Border (NDC 80777-0279-99)
Vaccine Wastage

- If vaccine expires, is wasted or is no longer authorized before you can use it:
  1. Process your COVID-19 vaccine waste through the reconciliation process in VOMS 2.0 in ASIIS. Please note that COVID-19 vaccines will not need to be returned if any are reconciled from the inventory using a return adjustment category.
  2. Dispose of the vaccine.
- Expired/wasted COVID-19 doses should be disposed of in a sharps container or per the hazardous waste policy in your office.
- Tear off the vial labels or mark the identifying information (lot number, NDC number, etc) with a black marker prior to disposing.
- Expired/wasted COVID-19 vaccines **DO NOT** go back to McKesson or Pfizer at this time.
ADHS Vaccine Reference Sheets - Pfizer-BioNTech

**Pediatric Pfizer Bivalent**
(Ages 6 mos - 4 years) - Maroon Cap
- [PEDIATRIC Pfizer Vaccine Reference Sheet](#)

**Pfizer Bivalent** (Ages 5-11) - Orange Cap
- [Pfizer Vaccine Reference Sheet](#)

**Pfizer Bivalent** (Ages 12+, No Diluent) - Gray Cap
- [Pfizer Vaccine Reference Sheet](#)
ADHS Vaccine Reference Sheets - Moderna

**Moderna Bivalent (Ages 6 months - 5 years) - Dark Pink Cap with Yellow Border on label**
- [Modernova Vaccine Reference Sheet](#)

**Moderna Bivalent (Ages 6 months +) - Dark Blue Cap**
- [Moderna Vaccine Reference Sheet](#)

<table>
<thead>
<tr>
<th>Vaccine Type</th>
<th>Cap Color</th>
<th>Temp Range</th>
<th>Additional Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderna Bivalent (Ages 6 months - 5 years)</td>
<td>Dark Pink</td>
<td>-50°C to -15°C</td>
<td>Until expiration. Check the Moderna website for the expiration date for storage in the freezer.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.0°C to 8.0°C</td>
<td>Store in refrigerator for up to 30 days if vial is not punctured. DO NOT REFREEZE.</td>
</tr>
<tr>
<td>Moderna Bivalent (Ages 6 months +)</td>
<td>Dark Blue</td>
<td>-15.0°C to -15.0°C</td>
<td>Until expiration. Check the Moderna website for the expiration date for storage in the freezer.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.0°C to 8.0°C</td>
<td>Store in refrigerator for up to 30 days if vial is not punctured. DO NOT REFREEZE.</td>
</tr>
</tbody>
</table>

**Thawing**

<table>
<thead>
<tr>
<th>Multi-dose vials</th>
<th>Temp Conditions</th>
<th>Additional Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-dose vial:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thaw in refrigerated conditions between 2.0°C to 8.0°C (36.0°F to 46.0°F) for 2 hours. If thawing in refrigerated conditions, let vials stand at room temp for 15 minutes before administering. OR Thaw at room temperature between 15.0°C to 25°C (59.0°F to 77.0°F) for 45 minutes. Unpunctured vials may be stored between 8.0°C to 25.0°C (46.0°F to 77.0°F) for a total of 24 hours.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.0°C to 8.0°C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Store in refrigerator for up to 30 days if vial is not punctured. DO NOT REFREEZE.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
COVID-19 Vaccine Program
ADHS COVID-19 Vaccine Website
azhealth.gov/covid19vaccine
ADHS Find Vaccine webpage [azhealth.gov/findvaccine]

- The locations of vaccination sites
- Filter to sort by vaccine type
- Use the patient portal at [podvaccine.azdhs.gov](http://podvaccine.azdhs.gov) to make an appointment for a relative
- Appointments recommended but no longer required at state-operated sites
All facilities must onboard to be able to order/administer COVID-19 vaccines

Pandemic Vaccine Provider Onboarding Tool - Job Aid (bottom right)

Wait until you’re at the facility to onboard so you can upload photos of inside and outside of units

Read through forms for important requirements

Note: Per the CDC Agreement, COVID-19 vaccines must be recorded in the vaccine recipient’s record, the required information reported to the relevant state, local, or territorial public health authority, and decremented from the inventory within 24 hours of administration.
Required Reporting

- ASIIS
  - for inventory accounting and dose administration data within 24 hours
    - Required even if you use an EHR, ADHS VMS app, etc.
    - Verify ASIIS Lot Number > Reconciliation page (ASIIS Inventory) numbers should be matched between the quantity on hand and physical inventory columns
  - Vaccine Inventory Management course in AIPO Train

- Vaccines.gov/CDC VaccineFinder monthly inventory by 4 a.m. ET on the second Wednesday of each month
- County surveys as required by your local jurisdiction

Your ASIIS inventory is used by local, state, and federal leaders to make vaccine ordering decisions - It MUST be accurate
COVID-19 Inventory Management Reminders

In order to ensure that provider sites are being good stewards of the COVID-19 vaccines, the CDC has emphasized that each COVID-19 vaccination site should have at most 3-4 weeks of vaccine inventory on hand.

- Place smaller, more frequent orders to avoid stockpiling doses
- Use the data in ASIIS to determine how many doses you use & how many doses are on hand to place an order for an appropriate amount of doses
- Use the ADHS vaccine transfer matchmaker website to request a smaller quantity of doses than can be ordered in ASIIS
- Administered doses must be entered in ASIIS within 24 hours and decremented from the ASIIS inventory
- CDC VaccineFinder (vaccines.gov) inventory must be updated weekly by Friday
- Wasted/Expired Doses must be reported on signed and complete wasted/expired forms weekly
Off-Label Use

Pandemic providers should be aware that they must use COVID-19 vaccines according to FDA and CDC guidance. Use of COVID-19 vaccines outside of FDA and CDC recommendations ("off label") is a violation of the provider agreement.

- Providers may not be covered under PREP Act and therefore not have the immunity from prosecution that the PREP Act provides.
- Recipients of an “off-label” COVID-19 vaccine dose may not be covered by the Countermeasure Injury Compensation Program if they were to have serious adverse events from the vaccine.
- Providers who violate the CDC agreement may not be able to remain as part of CDC programs.
- COVID-19 vaccine administration fees may not be covered if the dose were given “off-label.”
CDC Website: VFC vs. COVID-19 Vaccination Programs

- Separate programs with separate agreements
- Distinct requirements for each
- Help VFC providers understand difference between program requirements

Vaccines for Children Program vs. CDC COVID-19 Vaccination Program

As Emergency Use Authorization of COVID-19 vaccine products expand to include adolescents and children, it is critical to enroll providers in the COVID-19 Vaccination Program to ensure equitable access to COVID-19 vaccination services. Providers enrolled in the Vaccines for Children (VFC) program are well situated to serve in this capacity due to their direct access to the younger patient population and their familiarity with vaccine administration and federal vaccine programs. Though the VFC and COVID-19 Vaccination programs are both federal government programs, they have distinct requirements based on the associated funding legislation. For this reason, the provider agreements remain separate, and VFC providers must sign and adhere to the requirements of the CDC COVID-19 Vaccination Program Provider Agreement in order to receive and administer COVID-19 vaccines. The table below has been developed to assist VFC providers in understanding the difference in the programs’ requirements. Program differences are in bold.

<table>
<thead>
<tr>
<th>Vaccines &amp; Immunizations</th>
<th>VFC Program</th>
<th>COVID-19 Vaccination Program</th>
</tr>
</thead>
<tbody>
<tr>
<td>Training and Education</td>
<td>Providers enroll via state/local immunization program enrollment system and procedures.</td>
<td>Providers enroll via state/local immunization program enrollment system and procedures.</td>
</tr>
<tr>
<td>Vaccine Recipient Education</td>
<td>Providers must complete and sign state/local immunization program Vaccines for Children Program Provider Agreement and VFC Program Provider Profile Form.</td>
<td>Providers must complete and sign CDC COVID-19 Vaccination Program Provider Agreement, Sections A and B.</td>
</tr>
<tr>
<td>Health Departments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Planning &amp; Partnerships</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccine Effectiveness Research</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccination Toolkits</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Providers order routine childhood vaccines via state/local immunization program-designated ordering system and procedures. | Providers order COVID-19 vaccines via state/local immunization program-designated ordering system and procedures. |
- Providers must be fully trained in vaccine | Providers must be fully trained in vaccine.
The “organization email” listed in Section A of the CDC Agreement will get an email from vaccinefinder@auth.castlighthealth.com to sign up

- Weekly reporting by Friday of on-hand inventory quantities is a requirement
- Activating a location to display to the public is optional
- Providers can update display to the public function at any time
- Once COVID-19 vaccine locations are launched in Vaccines.gov, changes show publicly within 24 hours
- Check phone number in provider portal before making site public
- Vaccines.gov homepage - patients can find vaccines
- NOTE: If a site that is set to display to the public fails to update inventory within 72 hours, the availability information for each vaccine will display as “Call to confirm” on Vaccines.gov.

COVID-19 Administration Reporting Systems (CARS) Help Desk
- Monday through Friday, 8:00 am to 8:00 pm ET.
- CARS_HelpDesk@cdc.gov
- 1-833-748-1979
- Provide PIN when calling
The Bureau of Immunization Services (BIZS) is introducing changes to the required temperature incident reporting process for COVID-19 vaccine temperature incidents. This process is intended to improve incident turnaround times for providers by allowing them to take ownership of the process by following the steps in the Temperature Incident Instructions Checklist to obtain a viability determination from the manufacturer.

This is a required process for reporting all temperature incidents involving COVID-19 vaccines. The BIZS also encourages you to please fill out the survey at the end of the process as we value your feedback.
Daily COVID-19 Vaccine Tasks

**Temperature Monitoring**
- Twice per day monitor temperatures using the approved data logger
  - Document that you monitored temperatures using the paper temp log
    - Comirnaty/Pfizer ULT **Celsius, Fahrenheit**
    - Refrigerator **Celsius, Fahrenheit**
    - Moderna Freezer **Celsius Fahrenheit**
    - Document current, min, max, time, and initials
- **If there are out of range temperatures, stop using the vaccines and submit an incident report to the BIZS**
- Twice per month download and save the data logger data reports
  - Keep the data logger reports readily available for 6 years
  - Submit the data logger reports (in an acceptable file format: .xls, .txt, .ltd or .csv) to the BIZS upon request

**Take a physical inventory count of doses in the cold storage units**
- Compare the physical count to ASIIS lot number reconciliation inventory
- The inventories should be the exact same if doses given are entered properly in ASIIS. If you need to troubleshoot, use this job aid.
- Enter the weekly inventory by Fridays into CDC Vaccines.gov

**Document doses administered in ASIIS within 24 hours**
- Shipments must be marked “received” in ASIIS prior to administration in order for the doses to decrement from the inventory
If you would no longer like to participate as a pandemic provider please follow these steps

1. Account for all doses in ASIIS
   a. You are responsible for accounting for ALL of the doses shipped to you
   b. Ensure all doses shipped to the facility were received in ASIIS
   c. Ensure all doses administered were decremented from the ASIIS inventory
   d. ASIIS inventory reconciliation screen should be accurate

2. If you still have doses
   a. The doses will need to be transferred to another COVID-19 provider
   b. Transfers must have prior approval in ASIIS

3. Enter zero in CDC Vaccines.gov inventory when your inventory is depleted

4. Notify ADHS after doses have been accounted for
AIPOTrain

- Training on ordering, receiving, and accounting for doses in ASIIS
- Information on data loggers - setting up, downloading data
- Onboarding resources
- Mass immunizations

How to Register
1. Go to https://AIPO.myabsorb.com/?KeyName=PandemicProviders (This link automatically enters the enrollment key)
2. Enter required fields
3. Select Sign up
4. Click email activation link (important)

How to Log In
1. Go to https://AIPO.myabsorb.com/#/login
2. Enter username and password (username will be email address)
3. Select Log In

For existing AIPO Train users: Enter enrollment key “PandemicProviders” to access pandemic-specific training

Questions? Email AIPOTrain@azdhs.gov
Administration Fee

- CMS has a toolkit to help health care providers prepare to administer vaccines
- Vaccine doses given to the American people at no cost
- Providers contractually agree to administer a COVID-19 vaccine regardless of an individual's ability to pay and regardless of their coverage status
- May not seek any reimbursement, including through balance billing, from a vaccine recipient
- People without health insurance can get COVID-19 vaccine at no cost
- If you give COVID-19 vaccines to patients who are covered by AHCCCS you will need to be enrolled with AHCCCS in order to bill AHCCCS the administration fee
  - Register with AHCCCS here

Facilities cannot bill patients for the cost or admin fee for COVID-19 vaccines.
CVX Code and CPT Code Resources

- CMS - Helpful for Billing
- CDC - Helpful for Uploading Data in EHR and ASIIS
- ADHS - Arizona HL7 Specific Rules
TAPI - The Arizona Partnership for Immunizations (State immunization coalition)

- COVID-19 Resources
- COVID-19 Vaccine Billing Policy Information
- Resources for immunizations at off-site locations
CDC Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations

CDC has issued revised Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations to assist with jurisdictional planning and implementation of satellite, temporary, or off-site vaccination clinics by public and private vaccination organizations.

The guidance is broken down into four categories:

- Planning activities
- Pre-clinic activities
- During the clinic activities
- Post-clinic activities

The guidance also provides information on additional considerations required during the COVID-19 pandemic, including physical distancing, personal protective equipment (PPE), and enhanced sanitation efforts
Training for Healthcare Professionals

- CDC COVID-19 Vaccine Training Modules
- Public Health Foundation Training Plan
Immunization Action Coalition - [immunize.org](http://immunize.org)

- Info on administering vaccines
- Handouts for staff and patients
- “Ask the Experts” page
  - Includes **COVID-19 vaccines**
- Option to sign up for IAC Express email
  - Weekly email with updates to information and resources
CDC COVID-19 Vaccination Clinical Resources

COVID-19 Vaccination
Clinical Resources for Each COVID-19 Vaccine
Find information for COVID-19 vaccination administration, storage and handling, reporting, and patient education for each specific vaccine

Product Information by US Vaccine

ACIP Recommendations
Storage and Handling
General Vaccine Administration
Training and Education

V-safe
Clinical Considerations
Emergency Use Authorizations (EUAs)

Vaccination Provider Requirements & Support
Vaccination Data & Reporting Systems
Planning & Partnerships
Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States

Other resources:
- Summary Document for Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States
- COVID-19 Vaccine Administration Errors and Deviations

### COVID-19 vaccine products currently approved or authorized in the United States

<table>
<thead>
<tr>
<th>Age indication</th>
<th>Vaccine composition</th>
<th>Vaccine vial color</th>
<th>Label border color</th>
<th>Dilution required</th>
<th>Primary series</th>
<th>Booster doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months-4 years</td>
<td>Monovalent (Use for 1st and 2nd Dose)</td>
<td>Maroon</td>
<td>Maroon</td>
<td>Yes</td>
<td>Doses 1 and 2: 0.5 mL, Dose 3: 0.25 mL</td>
<td>NA</td>
</tr>
<tr>
<td>6 months-4 years</td>
<td>Bivalent (Use for 3rd Dose)</td>
<td>Maroon</td>
<td>Orange</td>
<td>Yes</td>
<td>Dose 3: 0.2 mL</td>
<td>NA</td>
</tr>
<tr>
<td>5-11 years</td>
<td>Monovalent</td>
<td>Orange</td>
<td>Orange</td>
<td>Yes</td>
<td>NA</td>
<td>10 µg</td>
</tr>
<tr>
<td>5-11 years</td>
<td>Bivalent</td>
<td>Orange</td>
<td>Orange</td>
<td>Yes</td>
<td>NA</td>
<td>10 µg</td>
</tr>
<tr>
<td>12 years and older</td>
<td>Monovalent</td>
<td>Gray</td>
<td>Gray</td>
<td>No</td>
<td>30 µg</td>
<td>NA</td>
</tr>
<tr>
<td>12 years and older</td>
<td>Bivalent</td>
<td>Gray</td>
<td>Gray</td>
<td>No</td>
<td>NA</td>
<td>30 µg</td>
</tr>
</tbody>
</table>

### Pfizer-BioNTech

<table>
<thead>
<tr>
<th>Age indication</th>
<th>Vaccine composition</th>
<th>Vaccine vial color</th>
<th>Label border color</th>
<th>Dilution required</th>
<th>Primary series</th>
<th>Booster doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months-5 years</td>
<td>Monovalent</td>
<td>Dark blue</td>
<td>Magenta</td>
<td>No</td>
<td>25 µg</td>
<td>0.25 mL</td>
</tr>
<tr>
<td>6 months-5 years</td>
<td>Bivalent*</td>
<td>Dark blue</td>
<td>Yellow</td>
<td>No</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>6-11 years</td>
<td>Monovalent</td>
<td>Dark blue</td>
<td>Purple</td>
<td>No</td>
<td>50 µg</td>
<td>0.5 mL</td>
</tr>
<tr>
<td>6-11 years</td>
<td>Bivalent</td>
<td>Dark blue</td>
<td>Gray</td>
<td>No</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>12 years and older</td>
<td>Monovalent</td>
<td>Red</td>
<td>Light blue</td>
<td>No</td>
<td>100 µg</td>
<td>0.5 mL</td>
</tr>
<tr>
<td>12 years and older</td>
<td>Bivalent</td>
<td>Dark blue</td>
<td>Gray</td>
<td>No</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

*Denotes a new formulation that has been approved for use in the United States.
CDC Vaccine Storage and Handling Toolkit

View or Print Toolkit

The Vaccine Storage and Handling Toolkit is a comprehensive guide that reflects best practices for vaccine storage and handling from Advisory Committee on Immunization Practices (ACIP) recommendations, product information from vaccine manufacturers, and scientific studies.

Vaccine Storage and Handling Resources

Access additional resources including web-based trainings, videos, checklists, and references related to vaccine storage and handling.

These example vaccine labels can be used to organize vaccines within the storage unit. Referenced in the storage and handling toolkit.

- [2020-2021 Influenza Season Vaccine Label Examples](#) [4 pages] (Sept 2020)
- [Vaccine Labels Examples](#) [20 pages] (Jan 2021)
Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites

- Emergency equipment that should be immediately available
- Routine observation periods following COVID-19 vaccination
- Early recognition of anaphylaxis
- Management of anaphylaxis at a COVID-19 vaccination location
- Considerations for anaphylaxis management in special populations
- Patient counseling
- Reporting anaphylaxis

Locations administering COVID-19 vaccines should adhere to CDC guidance, including screening recipients for contraindications and precautions, having necessary supplies and staff members available to manage anaphylaxis, implementing recommended post vaccination observation periods, and immediately treating suspected anaphylaxis with intramuscular epinephrine injection.
Give patients a **v-safe** information sheet at the time of vaccination

**Suggested healthcare provider script:**  **CDC has created a way for you to report how you feel after COVID-19 vaccination through a smartphone-based tool that uses text messaging and web surveys to check in with you.** Here (or in your packet) is a **v-safe** information sheet with more details and simple instructions to sign up.

**Parents and guardians can now enroll adolescents (ages 5 and older) in the v-safe after vaccination health checker℠ and complete health check-ins on their behalf after COVID-19 vaccination.**

**Poster and website translated into multiple languages**
VAERS accepts all reports from everyone regardless of the plausibility of the vaccine causing the event or the clinical seriousness of the event.
EUA Fact Sheets

Routine vaccines are given with a Vaccine Information Statement (VIS) COVID-19 vaccines under the Emergency Use Authorization (EUA) will be given with an EUA Factsheet.

- Pfizer EUA Fact Sheet
- Moderna EUA Fact Sheet
- Janssen EUA Fact Sheet
- Novavax EUA Fact Sheet
# Moderna Puncture Tracking Log

- Keep track of how many times vials have been punctured
- Vials can only be punctured maximum of 20 times
- Mark half-doses vs full doses
- Can track 2 vials per log

## Moderna Puncture Tracking Log

<table>
<thead>
<tr>
<th>Vial Lot #</th>
<th>Start Time</th>
<th>End Time</th>
<th>Dose</th>
<th>Full (0.5 mL)</th>
<th>Half (0.25 mL)</th>
<th>Vial Lot #</th>
<th>Start Time</th>
<th>End Time</th>
<th>Dose</th>
<th>Full (0.5 mL)</th>
<th>Half (0.25 mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td>5</td>
<td></td>
<td></td>
<td>6</td>
<td></td>
<td></td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td>9</td>
<td></td>
<td></td>
<td>10</td>
<td></td>
<td></td>
<td>11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td>14</td>
<td></td>
<td></td>
<td>16</td>
<td></td>
<td></td>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Reminders**
- Moderna booster doses are 0.25mL (half the dose size of a primary series dose)
- Moderna vials can only be punctured a maximum of 20 times
- Providers are responsible to keep track of the number of punctures for each vial
- Punctured Moderna vials can be used to administer both primary and booster doses
- Punctured Moderna vials must be used within 12 hours

Updated 12/2021

602-364-3899
ArizonaVFC@azdhs.gov
azdhs.gov/covid19/vaccines
You can only puncture the diluent once

Orders of Pfizer age 5-11 vaccine include ancillary kits that contain 10mL diluent vials. While these vials appear to contain sufficient diluent for multiple vials, they must only be used once.

- Diluent vials are a one-time-use item and should be discarded with the remaining content after each use.
- For each vial of vaccine, extract 1.3mL of diluent from a single-use vial to reconstitute 1.3mL of vaccine
- Do not be tempted to puncture diluent vials more than once.
COVID-19 Vaccine Transfer Matchmaker Tool

- Share vaccine with other active COVID-19 providers
- Request vaccine from nearby locations if active providers need vaccine
- You can transfer needles as well
- Only serves as connection between providers
- All transfers must still have prior approval in ASIIS, must follow all transfer steps
- Matchmaker Tool Job Aid
  - Transfer steps
  - Helpful resources linked

Do you have more vaccines than you can use? List them on the Arizona COVID-19 Vaccine Transfer Matchmaker Website using the "Add Vaccine/Needle" form on the website.

Do you need to place a vaccine order? First, check the Arizona COVID-19 Vaccine Transfer Matchmaker Website for vaccine available at a location near you, and submit a "Request Vaccine/Needle" form on the website. The table on the left shows vaccines that are available for providers to request.
ADHS Consent Form Template

- No Federal requirement for informed consent relating to immunization
- Available for providers who do not have own consent form
- Use with CDC Pre-Vaccination checklist
- Spanish ADHS consent form
- Spanish CDC Pre-Vaccination Checklist
ADHS Does Not Provide Exemption Forms for Adults for the COVID-19 Vaccine

- Individual facilities and employers may choose to set their own immunization requirements for adults
- If an employer is requiring a COVID-19 Vaccine for their employees, and the employee is refusing vaccination, direct that patient to their Human Resources department
- Adults who have questions on immunization exemptions, for any vaccine, should contact the facility or employer who has set the requirement
Standing Order Links - Pfizer-BioNTech

**Link to Pfizer**
(6 months - 4 years)

**Purpose**
- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP).

**Procedure**
- Note: Monovalent Pfizer-BioNTech COVID-19 Vaccine is no longer recommended and should not be used.
  - Assess children 6 months through 4 years of age for vaccination with Pfizer-BioNTech COVID-19 vaccine based on the following criteria:
  - Children who ARE NOT moderately or severely immunocompromised:
    - If the recipient has never received a COVID-19 vaccine, administer monovalent Pfizer-BioNTech COVID-19 Vaccine (Dose 1).

**Note:** Use these standing orders in conjunction with [Interim COVID-19 Immunization Schedule for Persons 6 Months and Older](https://www.cdc.gov/vaccines/schedules/full schedule.html).

---

**Link to Pfizer**
(5 years and older)

**Purpose**
- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP).

**Procedure**
- Note: Monovalent Pfizer-BioNTech COVID-19 Vaccine is no longer recommended and should not be used.
  - Assess persons 5 years of age and older for vaccination with Pfizer-BioNTech COVID-19 vaccine based on the following criteria:
  - Persons who ARE NOT moderately or severely immunocompromised:
    - If the recipient has never received a COVID-19 vaccine, administer monovalent Pfizer-BioNTech COVID-19 Vaccine (Dose 1).

**Note:** Use these standing orders in conjunction with [Interim COVID-19 Immunization Schedule for Persons 6 Months and Older](https://www.cdc.gov/vaccines/schedules/full schedule.html).
Standing Order Links - Moderna

Link to Moderna
Ages 6mos - 5yrs

6 Months Through 5 Years of Age
Bivalent Moderna COVID-19 Vaccine
Standing Orders for Administering Vaccine

<table>
<thead>
<tr>
<th>Bivalent Vaccine</th>
<th>Dose/Injection Amount</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blue capped vial with gray label</td>
<td>25 µg/0.25 mL</td>
<td>Intramuscular (IM) injection</td>
</tr>
<tr>
<td>Dark pink capped vial with yellow dose on the label</td>
<td>10 µg/0.2 mL</td>
<td>Intramuscular (IM) injection</td>
</tr>
</tbody>
</table>

NOTE: Use these standing orders in conjunction with Interim COVID-19 Immunization Schedule for Persons 6 Months and Older

Purpose
- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP).

Policy
- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the “Procedure” section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure
NOTE: Moderna Moderna COVID-19 Vaccine is no longer recommended and should not be used.

Assess children 6 months through 5 years of age for vaccination with Moderna COVID-19 Vaccine based on the following criteria:

Children who ARE NOT moderately or severely immunocompromised:

- If the recipient has received 2 previous doses of:
  - Monovalent Moderna COVID-19 vaccine, administer 1 dose of Bivalent Moderna COVID-19 Vaccine at least 8 weeks (2 months) after Dose 2.
  - If the Dose 2 vaccine product cannot be determined, is no longer available, or contraindicated, administer bivalent Moderna COVID-19 Vaccine at least 8 weeks after Dose 2.

Children who ARE moderately or severely immunocompromised:

- If the recipient has never received a COVID-19 vaccine, administer bivalent Moderna COVID-19 Vaccine (Dose 1).
- If the recipient has received 1 dose:
  - Monovalent or bivalent Moderna COVID-19 Vaccine, administer bivalent Moderna COVID-19 Vaccine (Dose 2) at least 4 weeks after Dose 1.
  - If the Dose 1 vaccine product cannot be determined, is no longer available, or contraindicated, administer bivalent Moderna COVID-19 Vaccine (Dose 2) at least 4 weeks (1 month) after Dose 1.
- If the recipient has received 2 doses of:
  - Moderna COVID-19 Vaccine, administer bivalent Moderna COVID-19 Vaccine (Dose 2) at least 4 weeks (1 month) after the second dose.

Link to Moderna
Ages 6 yrs and older

6 Years of Age and Older
Bivalent Moderna COVID-19 Vaccine
Standing Orders for Administering Vaccine

<table>
<thead>
<tr>
<th>Bivalent Vaccine</th>
<th>Dose/Injection Amount</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blue capped vial with gray-banded label</td>
<td>Ages 6–11 years: 25 µg/0.25 mL</td>
<td>Intramuscular (IM) injection</td>
</tr>
<tr>
<td>Ages 12 years and older: 50 µg/0.5 mL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Use these standing orders in conjunction with Interim COVID-19 Immunization Schedule for Persons 6 Months and Older

Purpose
- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP).

Policy
- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the “Procedure” section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure
NOTE: Moderna Moderna COVID-19 Vaccine is no longer recommended and should not be used.

Assess persons 6 years of age and older for vaccination with Moderna COVID-19 Vaccine based on the following criteria:

Persons who ARE NOT moderately or severely immunocompromised:

- If ages 6 through 14, additional doses are not currently recommended.
- If ages 15 or older, an additional bivalent mRNA vaccine dose may be given at least 4 months after the first dose of a bivalent mRNA vaccine.

Persons who ARE moderately or severely immunocompromised:

- If the recipient has never received a COVID-19 vaccine, administer 1 dose of bivalent Moderna COVID-19 Vaccine (Dose 1).
- If the recipient has received 1 previous dose of:
  - Monovalent or bivalent Moderna COVID-19 Vaccine, administer bivalent Moderna COVID-19 Vaccine (Dose 2) at least 4 weeks (28 days) after the Dose 1.
  - Monovalent or bivalent Pluristem Therapeutics/Novavax or Janssen COVID-19 vaccines, then bivalent Moderna COVID-19 Vaccine (Dose 2) may be administered.”
  - If the Dose 1 product cannot be determined, is no longer available, or contraindicated, administer bivalent Moderna COVID-19 Vaccine at least 4 weeks (28 days) after the first dose.
Standing Order Links - Novavax

[Image of Novavax COVID-19 Vaccine]

**Novavax COVID-19 Vaccine**

**Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older**

<table>
<thead>
<tr>
<th>Vaccine Product</th>
<th>Dose/Injection Amount</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blue cap/silver</td>
<td>5 µg and 10 µg of Matrix-M™ adjuvant</td>
<td>Intramuscular (IM) injection</td>
</tr>
</tbody>
</table>

**Purpose**

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP).

**Policy**

- Where authorized under state law, standing orders enable eligible nurses and other healthcare providers (e.g., pharmacist or pharmacy technicians) to vaccinate persons who meet the criteria established by ACIP. Providers are encouraged to contact their local or state health department for further guidance.

**Procedure**

- Assess persons 18 years of age and older for the vaccine with Novavax COVID-19 Vaccine based on the following criteria:
  - Persons who are HIV-positive or severely immunocompromised:
    - If the recipient has never received a COVID-19 vaccine, administer 1 dose of Novavax COVID-19 Vaccine.
    - If the recipient has received 1 previous dose of:
      - Novavax COVID-19 Vaccine, administer the second dose at least 2-4 weeks after the first dose.
      - A vaccine product that cannot be determined, no longer available or considered, administer Novavax COVID-19 Vaccine at least 4 weeks after the first dose.
  - Persons who are HIV-negative and not severely immunocompromised:
    - If the recipient has never received a COVID-19 vaccine, administer 1 dose of Novavax COVID-19 Vaccine.
    - If the recipient has received 1 previous dose of:
      - Novavax COVID-19 Vaccine, administer the second dose at least 2-4 weeks after the first dose.
      - A vaccine product that cannot be determined, no longer available or considered, administer Novavax COVID-19 Vaccine at least 4 weeks after the first dose.

- Persons with a history of myocarditis or pericarditis:
  - If history of prior COVID-19 vaccination, recipients Novavax COVID-19 Vaccine, after the episode of myocarditis or pericarditis has completely resolved.
  - If myocarditis or pericarditis occurred after the first dose of an mRNA or Novavax COVID-19 vaccine, generally receive a second vaccine dose. Due to limited data, it is recommended to consult with immunization experts for guidance on the second dose of an mRNA or Novavax COVID-19 vaccine.

- Additional clinical considerations:
  - For people who received a COVID-19 vaccine outside the United States, guidance can be found at [https://www.novavax.com/coronavirus-vaccines/clinical-considerations/](https://www.novavax.com/coronavirus-vaccines/clinical-considerations/)
  - Novavax COVID-19 Vaccine may be contraindicated with other recommended vaccines without regard to time.
  - For recommendations for COVID-19 vaccination and SARS-CoV-2 infection, see [https://www.cdc.gov/vaccines/vaccines-by-age/2021-revised.html](https://www.cdc.gov/vaccines/vaccines-by-age/2021-revised.html)
  - Persons who have received HCT or CAR-T cell therapy:
    - Recipients who have received doses of COVID-19 vaccine prior to or during receiving HCT or CAR-T cell therapy with any primary line of treatment 12 weeks after transplant or CAR-T cell therapy.
  - Screen for contraindications and precautions.

- Contraindications:
  - History of:
    - Severe allergic reaction (e.g., anaphylaxis) after a previous dose of a component of the COVID-19 vaccine
    - Known anaphylactic reaction to a component of the vaccine
Standing Order Links - Janssen

Link to Janssen

Janssen COVID-19 Vaccine (Johnson & Johnson)
Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Dosage (isseries/Route)</th>
<th>Joint CDC Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janssen COVID-19 Vaccine (Johnson &amp; Johnson)</td>
<td>0.5 mL IM injection</td>
<td>🚫</td>
</tr>
</tbody>
</table>
Janssen (Ages 18+)

- Janssen Vaccine Reference Sheet
- What Patients and Providers Need to Know About the Janssen Vaccine

**Vaccine Storage**

<table>
<thead>
<tr>
<th>Janssen COVID-19 Vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Refrigerator</strong></td>
</tr>
<tr>
<td>- 2.0° C to 8.0° C</td>
</tr>
<tr>
<td>- 36.0° F to 46.0° F</td>
</tr>
<tr>
<td>- Store in refrigerator for up to 11 months</td>
</tr>
<tr>
<td>- DO NOT REFREEZE</td>
</tr>
</tbody>
</table>

**Dosage**

- Each vaccine vial contains 5, 0.5mL doses to be administered
- No reconstitution required
- Discard any punctured vial held at refrigerator temperatures after 6 hours
- Discard any punctured vial held at room temperature (maximally 25°C/77°F) after 2 hours

**Administration**

- Standard needles and syringes
- Draw 0.5mL and inject intramuscularly (IM)
- Single dose
- For adults 18 and older
- Not for children
- Can be administered until 11:59 p.m. EST on expiry date. Expiry dates can be verified on the [Janssen website](https://www.janssen.com/)

The storage and handling information found on the Fact Sheet supersedes the storage and handling information on the carton and vial labels.

Disclaimer: Subject to change due to FDA EUA approval

UPDATED 4/12/22
Vaccine Manufacturer COVID-19 Websites

- Comirnaty/Pfizer COVID-19 Website
- Moderna COVID-19 Website
- Janssen COVID-19 Website
- Novavax COVID-19 Website
COVID-19 Vaccine Expiration Dates - Pfizer

**Pediatric Pfizer Maroon Cap Bivalent (Ages 6 months - 4 years)**
- Date printed on vial and tray is **manufacturing date only**
- Use the [Pfizer website](https://www.pfizer.com)

Base expiration date on storage method and manufacturing date. For example:
- If the manufacturer date is 8/2021 and the doses are stored in an ultra-low-temp freezer, the doses would expire April 30, 2022.
- If the doses are put in the refrigerator November 2, 2021, they would expire 10 weeks from November 2 on January 11, 2022.

**Pediatric Pfizer-BioNTech Bivalent (Ages 5 - 11 years) - Orange Cap**
- Date printed on vial and tray is the **expiration date**
- Use the [Pfizer website](https://www.pfizer.com) to double check expiration dates

**Pfizer-BioNTech Bivalent (Ages 12+, No Diluent) - Gray Cap**
- Date printed on vial and tray is the **expiration date**
- Use the [Pfizer website](https://www.pfizer.com) to double check expiration dates
COVID-19 Vaccine Expiration Dates - Moderna, Novavax and Janssen

**Moderna Bivalent Dark Pink Cap with Yellow Border on label (Ages 6 months - 5 years)**
- Use QR code
- Enter lot number on [expiration date checker website](#)

**Moderna Bivalent Dark Blue Cap (Ages 6 months+)**
- Use QR code
- Enter lot number on [expiration date checker website](#)

**Novavax**
- Use QR code
- Enter lot number on [expiration date checker website](#)

**Janssen**
- Use QR code
- Enter lot number on [expiration date checker website](#)
- Can be used until 11:59 EST on expiry date
Providers should check the latest expiry information on the manufacturer’s website before doses are removed from the unit.
COVID-19 Vaccine and Beyond-use Dates (BUDs)

- CDC has developed tracking labels refrigerators and freezers to help monitor and document cold storage dates
- Assist with documenting transportation time and temperature
- Available for both Moderna and Pfizer vaccines
- **Moderna COVID-19 Vaccine: Beyond Use Date/Time (BUD) Tracking Label for Vaccine During Refrigerator Storage** (cdc.gov)
- **Pfizer-BioNTech COVID-19 Beyond Use Date/Time (BUD) Tracking Labels for Vaccine During Freezer or Refrigerator Storage** (cdc.gov)
# Returning Thermal Shipping Containers (Once Empty)

<table>
<thead>
<tr>
<th>Company</th>
<th>Details</th>
</tr>
</thead>
</table>
| Pfizer  | - Shippers **DO NOT** need to be returned  
          - Only controlant data logger needs to be returned |
| Moderna | - Shippers do not need to be returned |
| Janssen | - Shippers do not need to be returned |
| Novavax | - Shippers do not need to be returned |
Vaccine Process

Vaccines are widely available

- Providers enter their COVID-19 vaccine order in ASIIS/VOMS 2.0
- BIZS will approve the order
- The order goes to CDC to Distributor/Manufacturer
- The order is shipped (will show in ASIIS/VOMS 2.0)
- Provider receives shipment of ancillary kit and vaccine (may not be same day)
- Provider logs into ASIIS/VOMS 2.0 to mark doses as “received”
- Provider administers vaccine
- Provider reports the administered vaccine to ASIIS through their EHR, State VMS POD application, directly in ASIIS or using Mass Immunization Module in ASIIS
- The dose is subtracted from the ASIIS inventory if properly recorded in a patient’s ASIIS record
ASIIS Information
Placing Orders in ASIIS

- Providers who have an approved onboarding submission are able to order vaccines

- AIPO Train courses
  - How to Place an Order in ASIIS
  - Vaccine Inventory Management - information on ordering and inventory reconciliation
  - Sign up for Dose Accountability Webinar
    - Recordings available any time within AIPO Train course
  - Included in Pandemic Provider course bundle

- Use COVID-19 Vaccine Presentations Job Aid to help make ordering decisions
Pfizer pediatric doses (5-11) should NOT be reported as adult doses

Reminder:

The CPT and CVX codes for the Pfizer age 5-11 vaccine and the Pfizer age 12+ vaccine are different.

Please ensure that your EHR has been updated to document the vaccines correctly.

For information on Arizona HL7 Specific Rules for Version 2.5.1, click here.

For information on List of Vaccine Names, Best ASIIS Selection and CPT/CVX Codes, click here.
Vaccine Transfer Process

- Both the sending and receiving providers will email data logger reports to ArizonaVFC@azdhs.gov
- Transfers must be approved in ASIIS prior to moving the doses
  - Enter the transfer in ASIIS prior to moving the doses
    - Information you will need for ASIIS
      1. The organization and facility sending the doses
      2. The organization and facility receiving the doses
      3. The quantity
      4. The lot number
  - When the doses arrive, mark them “received” in ASIIS. Do not administer doses before “receiving” them in the ASIIS inventory
- Only onboarded, active COVID-19 vaccine providers may receive COVID-19 vaccines
- Follow the USP transfer guidelines when packing the doses for transfer
  - Once frozen doses have been thawed they cannot go back into a freezer
- Wherever the vaccines are, data loggers must be with them to monitor the temperatures
- The ancillary kit must also be transferred with the doses
Correcting Negative Doses in ASIIS

Reconciling ASIIS inventory

- Giving more doses than what is in the ASIIS inventory will make the inventory negative, which will mean you cannot submit inventory reconciliation
- Only if extracting extra doses from a vial
  - Ex. Extracting 15 doses from Moderna 14-dose vial
- AIPO Train module: Correcting Negative COVID-19 Doses in ASIIS
How to Run Reminder/Recall Report

- ASIIS Reminder/Recall Reports AIPO Train course
- Identify patients due/past due for vaccines
- Schedule patients
- Create letters, postcards, and mailing labels
If your ASIIS Inventory is not accurate

- Doses that have been administered to patients should not be removed from the Reconciliation page (Inventory) in ASIIS

- Troubleshoot why the doses did not decrement
  - Register for Dose Accountability Webinar in AIPO Train
  - Past Dose Accountability Webinar videos in course module

- **Job aid** to walk you through process of searching/adding/editing patient records manually in ASIIS
Mark doses as *Received* in VOMS 2.0 when the doses arrive

- **Required regardless what system you use to document vaccine administration (EHR, VMS, ASIIS)**

- **When the doses arrive, mark them as *Received* in VOMS 2.0**
  - Log into ASIIS
  - Go to Inventory Management > VOMS 2.0 > Orders & Transfers > Click Receive button under Action header for the Inbound Order/Transfer
  - Verify the expiration date, lot number, and quantity of doses
  - Click the *Receive* button to receive the doses into the ASIIS Inventory

- **After the doses are *Received* in VOMS 2.0, you may administer them**

- **If you administer doses before they are *Received* into the ASIIS inventory, they will not decrement from the ASIIS inventory**
Funding Source - PAN

- The funding source should be PAN.
- If you have an EHR, your EHR vendor should send the code VXC50. On the user interface side, you will select PAN when administering.
- If you select VFC, State, Private, or something else as the funding source, the doses will not decrement from the ASIIS inventory.
Communication Resources
The BIZS sends granicus updates (email updates) on a variety of topics including COVID-19 vaccines, ASIIS, routine vaccines, etc. This library can be accessed at any time with the above link to view previously sent updates.
Ad Council COVID-19 Vaccination Campaign: It’s Up to You
getvaccineanswers.org

- Campaign site for consumers
- Answers common questions
- Provides vaccine information
- Link to Spanish site - www.DeTiDepende.org
- Creative materials that can be shared/used by providers
COVID-19 Vaccine Confidence Toolkit for Rural Jurisdictions

- Print ads
- Posters
- Brochure
- Social media posts
- Online resource guide
- PDFs can be customized using Adobe Acrobat Pro

Learn. Understand. Decide

COVID-19 vaccine communication toolkit

Customize the templates within the COVID-19 vaccine toolkit to easily develop internal and external communication materials.

With the support of the Delta Regional Authority (DRA) and the Health Resources Services Administration’s Federal Office of Rural Health Policy (FORHP), the Delta Beacon Community Health Systems Development (DBCHSD)
ADHS COVID-19 Communication Resources

- Posters in English and Spanish (sample [here](#))
- Addressing Misinformation ([here](#))
- Answering Patient Questions ([here](#))
- What to Expect After Getting COVID Vaccine ([here](#))
- What to Expect at Your Vaccine Appointment ([here](#))
- Vaccination Quick Answers ([here](#))
- Answering Common Patient Questions ([here](#))

COVID-19 Vaccine - Providers’ Toolkit

- Order Form to request materials for your facility
HHS Video “Tell Me More About Vaccines”

The video answers commonly asked questions about the COVID-19 vaccine. The video shares why vaccines are so important and provides expert commentary and graphic illustration to help viewers understand the science of vaccine development. Tune in to hear from various experts, including Dr. Anthony Fauci (NIH), Dr. Stephen Hahn (FDA), and Dr. Robert Kadlec (ASPR), on the steps researchers and scientists are taking to develop a safe and effective vaccine. You are encouraged to add the video link to your website or promote it on social media.
FDA Emergency Use Authorization for Vaccines Explained

- What is an Emergency Use Authorization?
- Are the COVID-19 vaccines rigorously tested?
- What safety and effectiveness data are required to be submitted to FDA for an EUA request for a vaccine intended to prevent COVID-19?
CDC COVID-19 Vaccination Communication Toolkits

- For Medical Centers, Clinics, Pharmacies, and Clinicians
- For Healthcare Professionals and Pharmacists
- For LTCF Administrators and Leadership
- For Employers of Essential Workers
- For Staff of Organizations Serving Communities
- Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit

The toolkit contains a variety of resources that you can use virtually or in person (with proper COVID-19 safety precautions):

- Posters
- FAQ
- Key messages
- Slide decks

Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit

As parents’ most trusted source of information on vaccines, pediatric healthcare professionals play a critical role in helping parents/guardians understand the importance of COVID-19 vaccination and assuring them that COVID-19 vaccines are safe and effective.

Your strong recommendation is critical for vaccine acceptance. Tell parents/guardians how important COVID-19 vaccines are to protecting their children’s health.

Remind parents that after their family is fully vaccinated against COVID-19, they may start to do some things they had stopped doing because of the pandemic.

Even if you are not administering COVID-19 vaccines, you can help parents/guardians feel confident in choosing to get their children vaccinated against COVID-19 by addressing their questions and assuring them of the safety and effectiveness of COVID-19 vaccines.

The materials on this page will help you share clear and accurate information about COVID-19 vaccines when starting or continuing conversations with parents/guardians, as well as information for those who choose not to vaccinate their child.

COVID-19 Vaccination of Minors

Patients, parents, and guardians may have questions about consent for vaccination for minors recommended to receive a COVID-19 vaccine. Learn more at: Pfizer-BioNTech COVID-19 Vaccine.
Provider Resources for Patient Conversations About COVID-19 Vaccines

- How to talk to your patients about COVID-19 vaccination

CDC's Key Points to Communicate to Your Patients:
- COVID-19 vaccines are safe and effective.
- Individuals 12 and up are all eligible to get a COVID-19 vaccination.
- There are many locations to find a COVID-19 vaccine.
- Having some side effects after vaccination is normal.
- You are not fully vaccinated until 2 weeks after the 2nd dose of a two-dose vaccine or 2 weeks after a one-dose vaccine.
CDC COVID-19 Vaccine Web Pages for the general public

- Benefits of Getting a COVID-19 Vaccine
- How COVID-19 Vaccines Work
- Frequently Asked Questions about COVID-19 Vaccination
- Understanding MRNA vaccines
- What to Expect at Your Appointment to Get Vaccinated for COVID-19
  - Translated in many languages
- When You’ve Been Fully Vaccinated
- Webpage COVID-19 Vaccines for Children and Teens
FAQs
FAQs

Q: If I am a VFC provider and already have an ASIIS PIN, do I still need to onboard?
   ● A: Yes. If a facility location wants to administer COVID-19 vaccines, they will need to onboard and sign the CDC COVID-19 Agreement. The VFC Program and the COVID-19 vaccine program are separate programs with separate signed Agreements.

Q: How do I order COVID-19 vaccines in ASIIS?
   ● A: Onboarded and active COVID-19 providers can follow the instructions in this job aid on how to place orders.

Q: Where can I find these slides?
   ● A: These slides can be found at azdhs.gov/covid19vaccine on the Provider Resources page. You can also find a link to the slides and the most recent recording in the Pandemic Provider Weekly Brown Bag course in AIPO Train.
THANK YOU!